Date:10/29/2009

or Qutenza with the FDA, including the PDUFA date for the NDA; plans and timing for commercialization of Qutenza; and development activities for NGX-1998 and other product candidates, including regulatory submissions and any outcomes of such submissions. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: positive results in clinical trials may not be sufficient to obtain FDA approval; the FDA may request additional clinical trials or other information prior to granting approval for Qutenza; any regulatory approvals which are received may be limited to certain indications; NeurogesX' product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy or tolerability; physician or patient reluctance to use Qutenza or NGX-1998, if approved; and other difficulties or delays in, clinical development of, and obtaining regulatory approval for NeurogesX' product candidates. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

    NeurogesX, Inc.                     The Ruth Group
    Stephen Ghiglieri                   Sara Pellegrino (investors)
    Chief Financial Officer             (646) 536-7002
    (650) 358-3310                      spellegrino@theruthgroup.com

                                        Jason Rando (media)
                                        (646) 536-7025
                                        jrando@theruthgroup.com

SOURCE NeurogesX, Inc.

'/>"/>

SOURCE NeurogesX, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. NeurogesX to Present at UBS Global Life Sciences Conference
2. NeurogesX to Present at Upcoming Fall Conferences
3. NeurogesX Appoints New Board Director and Audit Committee Chairman
4. NeurogesX Reports Second Quarter 2009 Results
5. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
6. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
7. NeurogesX Added to Russell 3000 Index
8. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
9. NeurogesX to Present at Needham Life Sciences Conference
10. NeurogesX Receives European Commission Approval for Qutenza(TM)
11. NeurogesX Reports First Quarter 2009 Results